Man

Marcelo Adan Garrido Salvo

Director

CENTRO DEL CÁNCER, PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE

Santiago, Chile

Líneas de Investigación


Gastric cancer treatments, tumor heterogeneity and targeted therapies, precision oncology

Educación

  •  Medico cirujano, UNIVERSIDAD AUSTRAL DE CHILE. Chile, 1997
  •  Internal Medicine, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE. Chile, 2001
  •  Sub-Specialization in Oncology and Hematology, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE. Chile, 2007
  •  Medicine, UNIVERSIDAD AUSTRAL DE CHILE. Chile, 1995
  •  Training in gastrointestinal Oncology and Neuroendocrine Tumors, Hospital Universitario Central de Asturias. España, 2013

Experiencia Académica

  •   Instructor Full Time

    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

    Medicina

    Santiago, Chile

    2003 - 2007

  •   Profesor Asistente Full Time

    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

    Medicina

    Santiago, Chile

    2007 - 2018

  •   Full professor of Dirección Innovación y Transferencia Tecnológica Full Time

    UNIVERSIDAD MAYOR

    Santiago, Chile

    2021 - A la fecha

  •   Associated Professor Full Time

    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

    Medicina

    Santiago, Chile

    2019 - 2021

Experiencia Profesional

  •   Medico intensivista Full Time

    HOSPITAL DE LOS ANDES

    Los Andes, Chile

    2002 - 2003

  •   Medical director Part Time

    Centro de Oncología de Precisión, Universidad Mayor

    Santiago, Chile

    2021 - A la fecha

  •   Chief of Onco-Hematology, Medical Oncology and Gastrointestinal Oncology Part Time

    Clínica Indisa

    Santiago, Chile

    2021 - A la fecha

  •   Principal Investigator Part Time

    Centro de Estudios Clínicos SAGA

    Santiago, Chile

    2021 - A la fecha

  •   Gastrointestinal Oncology and Oncology Clinical Trials Part Time

    Red de Salud UC Christus (Clinica San Carlos de Apoquindo)

    Santiago, Chile

    2014 - 2021

Premios y Distinciones

  •   Beca Presidente de la Republica

    Gobierno de Chile

    Chile, 1992

    Beca de estudios entregada por S.E. Presidente Patricio Aylwin Azocar

  •   Premio al mejor graduado

    UNIVERSIDAD AUSTRAL DE CHILE

    Chile, 1995

    Premio al mejor graduado de Medicina

  •   Beca Medicina Interna

    MINISTERIO DE SALUD

    Chile, 1998

    Beca de Medicina interna UC

  •   Beca de Oncologia

    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

    Chile, 2004

    Beca del Departamento de Hematologia y Oncologia PUC

  •   Prominent Oncologist Prize

    Sociedad Latinoamericana de Oncología Gastroenterológica

    Chile, 2019

    Prominent Oncologist Prize given by the Sociedad Latinoamericana de Oncología Gastroenterológica for his contribution to the field


 

Article (84)

<i>Porphyromonas gingivalis</i>, a bridge between oral health and immune evasion in gastric cancer
Assessing the Occurrence and Influence of Cancer Chemotherapy-Related Pharmacogenetic Alleles in the Chilean Population
Quadruple therapies show a higher eradication rate compared to standard triple therapy for <i>Helicobacter pylori</i> infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus
Differentially Expressed Genes and Signaling Pathways Potentially Involved in Primary Resistance to Chemo-Immunotherapy in Advanced-Stage Gastric Cancer Patients
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649
Impact of Adjuvant FOLFOX on Quality of Life and Peripheral Neuropathy Incidence in Patients With Gastric Cancer: A Prospective Cohort Study
Local advances and challenges in the molecular diagnosis of solid tumors: a health perspective towards precision oncology in Chile
Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab plus Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
First-line treatment with immune checkpoint inhibitors (ICI) for metastatic gastric and esophagogastric junction (EGJ) adenocarcinoma in Latin America: Sociedad Latinoamericana de Gastroenterologia Oncologica (SLAGO) evidence-based recommendations
Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial
Proteogenomic analysis in an early onset diffuse gastric cancer patient revealed alterations in PIK3R1, TP53, SMAD4 and a potential role of the PI3K-AKT and EGFR pathways: a case report
The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally
A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer
Case Report: Molecular Features and Treatment Options for Small Bowel Adenocarcinoma
CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20).
Clinical Presentation and Perioperative Management of Pheochromocytomas and Paragangliomas: A 4-Decade Experience
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240
Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.
Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.
Oncological resection, myasthenia gravis and staging as prognostic factors in thymic tumours: a Chilean case series
Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data
Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.
Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.
Update on neuroendocrine tumors
A molecular classification of gastric cancer in Chilean patients
A Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability
Clinical, biological and translational significance in gastric cancer of <i>reprimo</i>-<i>like</i> gene, an uncharacterized member of the <i>reprimo</i> gene family
Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non-Small-Cell Lung Cancer
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
First-line endocrine therapy for advanced breast cancer. A real-world study at a Latin American university health institution
Living Donor Liver Transplantation for Imatinib-Resistant Gastrointestinal Stromal Tumor Liver Metastases: A New Therapeutic Option in Transplant Oncology
Modulation of glycosyltransferase ST6Gal-I in gastric cancer-derived organoids disrupts homeostatic epithelial cell turnover
Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Retrospective Analysis of Chilean and Mexican GI Stromal Tumor Registries: A Tale of Two Latin American Realities
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
The Reprimo-Like Gene Is an Epigenetic-Mediated Tumor Suppressor and a Candidate Biomarker for the Non-Invasive Detection of Gastric Cancer
Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective
High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study
Identification of c.1531C>T Pathogenic Variant in the CDH1 Gene as a Novel Germline Mutation of Hereditary Diffuse Gastric Cancer
Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer
Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
Chilean Gastric Cancer Task Force A study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Angiogenesis inhibitors in early development for gastric cancer
Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer
A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma
Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy
Prediction of chemotherapy response and metabolism for the tailoring of ovarian cancer treatment
Prediction of Serious Complications in Patients With Seemingly Stable Febrile Neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a Prospective Cohort of Patients From the FINITE Study
In vitro cell response to chemotherapeutic agents, to personalize ovarian cancer treatment. Report of two cases
Metformin, at Concentrations Corresponding to the Treatment of Diabetes, Potentiates the Cytotoxic Effects of Carboplatin in Cultures of Ovarian Cancer Cells
Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases
Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays
Etiology of febrile neutropenia episodes among cancer patients from Hospital Clinico Universidad Catolica, Santiago-Chile
Etiología de episodios de neutropenia febril en pacientes adultos con cáncer hematológico y de órganos sólidos en el Hospital Clínico Universidad Católica, Santiago-Chile.
Invasive fungal disease in hemato-oncological and hematopoietic stem cell transplantation patients from Hospital Clinico Universidad Catolica, Santiago-Chile using revised EORTC/MSG diagnostic criteria
Cytokeratin 20 as a marker of tumor progression or dissemination in patients with colorectal cancer
Postoperative radio-chemotherapy in locally advanced gastric cancer
Prolonged survival of a woman with lung cancer diagnosed and treated with chemotherapy during pregnancy - Review of cases reported
Radio-quimioterapia postoperatoria en cáncer gástrico localmente avanzado
Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer - Case report
Nuevas alternativas en el tratamiento del cancer gástrico avanzado
Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4 chemotherapy)
Treatment of metastatic gastrointestinal stromal tumors with Imatinib. Report of four cases

Abstract (11)

Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.
Galectin 9 associates with PDL1 expression and promotes gastric cancer cell invasion
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
Development and validation of a Clinical Index of Severe Febrile Neutropenia: A prospective multicenter study
KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1-positive NSCLC after platinum-based therapy
Personalized cancer therapy for ovarian cancer patients
Second-line FOLFOX chemotherapy in patients with metastatic gallbladder cancer and cholangiocarcinoma
Systemic Therapy in Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) and Ki Index 5-10%
Evaluation of reprimo, a p53-dependent G2 arrest mediator candidate, for monitoring response to treatment in gastric carcinoma
Adjuvant chemoradiotherapy for gastric adenocarcinoma, toxicity, survival and prognostic factors

ConferencePoster (2)

Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses

Proyecto (4)

A molecular subtype associated with p53 alterations identifies gastric cancer patients with poor response to chemotherapy plus immunotherapy treatments
Mechanisms of resistance to immunotherapy based on checkpoint inhibitors in metastatic gastric cancers
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/​Esophagus Junction Cancer (CheckMate649)
ROLE OF REPRIMO, A P53-DEPENDENT G2 ARREST MEDIATOR CANDIDATE, IN THE PATHOGENESIS OF HUMAN GASTRIC CARCINOMA.

Review (1)

Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer
98
Marcelo Garrido

Director

CENTRO DEL CÁNCER, PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE

Santiago, Chile

10
Cesar Sanchez

Profesor asistente

Hematologia-oncologia

PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

santiago, Chile

9
Bruno Nervi

Associated Professor

Hematology - Oncology

Pontificia Universidad Catolica de Chile

Santiago, Chile

9
Gareth Owen

Profesor Titular

Fisiologia

PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE

Santiago, Chile

9
Matías Muñoz

Research Assistant

Universidad Mayor de Chile

Santiago, Chile

5
Francisco Acevedo

Medico Oncologo

Hemato Oncologia

Pontificia Universidad Católica de Chile

Santiago, Chile

4
Pamela Salman

Full Professor

Facultad de Medicina y Ciencias de la Salud

Universidad Mayor de Chile

Santiago, Chile

4
Miguel Cordova

Estudiando de Doctorado

Departamento de Posgrado

Universidad de Chile

Santiago, Chile

4
Mauricio Pinto

Investigador

STORM SPA

Santiago, Chile

4
ALEJANDRO CORVALAN

Principal Investigator

Hematology and Oncology

Pontificia Universidad Catolica de Chile

Santiago, Chile

4
Ignacio Retamal

Assistant Professor

Centro de Oncología de Precisión

Universidad Mayor de Chile

Santiago, Chile

3
Ricardo Armisen

Associate Professor

Centro de Genética y Genómica

Universidad del Desarrollo

Santiago, Chile

3
Juan Roa

Chair

Pathology

Pontificia Universidad Catolica de Chile

santiago, Chile

3
Valeria Matus

Associate Researcher

Hematology-Oncology

P. UNIVERSIDAD CATÓLICA DE CHILE

Santiago, Chile

3
María Maturana

Bioquimico

Pontificia Universidad Católica de Chile

Santiago, Chile

2
Charlotte Hill

Postdoctoral Fellow

CIIB

Universidad de Los Andes

Santiago, Chile

2
MARIA DURAN

Estudiante

Universidad Mcgill

Montreal, Canada

2
Olga Panes

Technical Director/ Associated Research

Hematology-Oncology

PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE

Santiago, Chile

2
Diego Mezzano

Director

Hematology-Oncology

PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE

Santiago, Chile

2
Luis Quinones

PROFESOR TITULAR

ONCOLOGIA BASICO-CLINICA

UNIVERSIDAD DE CHILE

Santiago, Chile

2
JUVENAL RÍOS

Investigador

CR de Investigación y Desarrollo

Instituto Nacional del Cáncer (INCANCER)

Santiago, Chile

2
Nicolas Jarufe

Chief Digestive Surgery

PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE

Santiago, Chile

2
Tomas de Mayo

PROFESOR ASOCIADO

CIENCIAS

UNIVERSIDAD MAYOR

SANTIAGO, Chile

2
Erica Koch

Oncólogo Médico

Red de Salud UC Christus

Santiago, Chile

2
María Rodríguez

Profesora Asociada

PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

Santiago, Chile

2
FERNANDO CROVARI

Jefe Departamento

Cirugía Digestiva

Pontificia Universidad Católica de Chile

Santiago, Chile

2
Patricio Yañez

Director Programa Sub-especialidad en Oncología Médica

Especialidades Médicas

Universidad de La Frontera

Temuco, Chile

2
José Clavero

Jefe Unidad

Cirugía

Clínica Universidad de Los Andes

Santiago, Chile

1
Leonel Muñoz

Profesor Adjunto

Escuela de Medicina

Universidad de Valparaíso

Viña del Mar, Chile

1
Ana Guzman

MÉDICO JEFE LABORATORIO

LABORATORIO CLÍNICO

PONTIFICIA UNIVERSIDAD CATÓLICA

SANTAIGO, Chile

1
Natalia Landeros

Profesor auxiliar

Facultad de Medicina

Universidad Católica del Maule

Talca, Chile

1
Pamela Zúñiga

Profesor Asociado

Pediatria

Pontificia Universidad Católica de Chile

Santiago , Chile

1
José Zoroquiain

PONTIFICIA UNIVERSIDAD CATÓLICA

SANTIAGO, Chile

1
Thomas Uslar

Académico

Endocrinología

Pontificia Universidad Católica de Chile

Santiago, Chile

1
Martin Dib

Jefe Programa de Trasplantes UC

Cirugía Digestiva

Pontificia Universidad Católica de Chile

Santiago, Chile

1
Francisco Barrera

Profesor Asociado

Gastroenterología

Pontificia Universidad Católica de Chile

Santiago, Chile

1
Manuel Espinoza

Profesor Asociado

Salud Pública

PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

Santiago, Chile

1
Martin Inzunza

Fellow simulación

Cirugía

Pontificia Universidad Católica de Chile

Santiago, Chile

1
Helga Weber

Investigador

Vicerrectoría de Investigación y Post Grado

Universidad de la Frontera

Temuco, Chile

1
Alberto Martin

Associate professor

Centro Ciencia & Vida

Universidad San Sebastián

Santiago, Chile

1
Ismael Riquelme

Académico - Investigador

Ciencias de la Salud

UNIVERSIDAD AUTÓNOMA DE CHILE

Temuco, Chile

1
Rafaela Erices

Postdoctorante

Ginecología y Obstetricia

Pontificia Universidad Católica de Chile

Santiago, Chile

1
Carolina Bizama

Assistant professor

Department of Pathology

PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

Santiago, Chile

1
Patricia García

Profesor Asistente

ANATOMIA PATOLOGICA

PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

SANTIAGO, Chile

1
Jaime Pereira

Jefe

Hematología-Oncología

ESCUELA DE MEDICINA, PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE

Santiago, Chile

1
Franz Villarroel

Jefe Laboratorio - PI

Departamento de Investigación del Cáncer

Fundación Arturo López Pérez

Santiago, Chile

1
Carolina Serrano

Profesor Asistente Ordinario

Pediatric Gastroenterology and Nutrition

PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE

Santiago, Chile

1
Arnoldo Riquelme

Profesor titular

Gastroenterología

PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE, DEPARTAMENTO DE GASTROENTEROLOGÍA

Santiago, Chile

1
Patricia García

Jefe de Laboratorio de Microbiologia

Escuela de Medicina

PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE, LABORATORIO DE MICROBIOLOGÍA

Santiago, Chile

1
Ignacio Wichmann

Assitant Professor

Obstetrics

Pontificia Universidad Católica de Chile

Santiago, Chile

1
jose valbuena

Associate Professor

Anatomic Pathology

PONTIFICIA UNIVERSIDAD CATOLICA. FACULTAD DE MEDICINA/ESCUELA DE MEDICINA/ DEPARTAMENTO DE ANATOMÍA PATOLÓGICA

santiago, Chile

1
Eduardo Aranda

Biochemist

Hematology

P. UNIVERSIDAD CATOLICA DE CHILE

Santiago, Chile

1
Mauricio Hernandez

Chief Laboratory Officer

Proteogenomica

MELISA Institute

San Pedro de la Paz, Chile

1
Ivania Valdes

Estudiante de Doctorado

Vicerrectoria de investigación

Universidad Mayor de Chile

Santiago, Chile

1
Sergio Riveros

Residente

Cirugía Digestiva

Pontificia Universidad Católica de Chile

Santiago, Chile